ArticleCell reports. Medicine2025

The potential of lazertinib and amivantamab combination therapy as a treatment strategy for uncommon EGFR-mutated NSCLC.

Seung Yeon Oh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.